Therapeutics for graft-versus-host disease: From conventional therapies to novel virotherapeutic strategies

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has a curative potential for many hematologic malignancies and blood diseases. However, the success of allo-HSCT is limited by graft-versus-host disease (GVHD), an immunological syndrome that involves inflammation and tissue damage mediated by donor lymphocytes. Despite immune suppression, GVHD is highly incident even after allo-HSCT using human leukocyte antigen (HLA)-matched donors. Therefore, alternative and more effective therapies are needed to prevent or control GVHD while preserving the beneficial graft-versus-cancer (GVC) effects against residual disease. Among novel therapeutics for GVHD, oncolytic viruses such as myxoma virus (MYXV) are receiving increased attention due to their dual role in controlling GVHD while preserving or augmenting GVC. This review focuses on the molecular basis of GVHD, as well as state-of-the-art advances in developing novel therapies to prevent or control GVHD while minimizing impact on GVC. Recent literature regarding conventional and the emerging therapies are summarized, with special emphasis on virotherapy to prevent GVHD. Recent advances using preclinical models with oncolytic viruses such as MYXV to ameliorate the deleterious consequences of GVHD, while maintaining or improving the anti-cancer benefits of GVC will be reviewed.

Original languageEnglish (US)
Article number85
JournalViruses
Volume8
Issue number3
DOIs
StatePublished - Mar 1 2016
Externally publishedYes

Fingerprint

Graft vs Host Disease
Hematopoietic Stem Cell Transplantation
Myxoma virus
Oncolytic Viruses
Transplants
Therapeutics
Hematologic Diseases
Neoplasms
Hematologic Neoplasms
HLA Antigens
Lymphocytes
Inflammation

Keywords

  • Allo-HSCT
  • Allogeneic
  • Cancer
  • GVC
  • GVHD
  • Hematopoietic cell transplant
  • MYXV

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Cite this

Therapeutics for graft-versus-host disease : From conventional therapies to novel virotherapeutic strategies. / Villa, Nancy; Rahman, Masmudur; McFadden, Douglas; Cogle, Christopher R.

In: Viruses, Vol. 8, No. 3, 85, 01.03.2016.

Research output: Contribution to journalReview article

@article{c22ae967254849919d13fb114174d993,
title = "Therapeutics for graft-versus-host disease: From conventional therapies to novel virotherapeutic strategies",
abstract = "Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has a curative potential for many hematologic malignancies and blood diseases. However, the success of allo-HSCT is limited by graft-versus-host disease (GVHD), an immunological syndrome that involves inflammation and tissue damage mediated by donor lymphocytes. Despite immune suppression, GVHD is highly incident even after allo-HSCT using human leukocyte antigen (HLA)-matched donors. Therefore, alternative and more effective therapies are needed to prevent or control GVHD while preserving the beneficial graft-versus-cancer (GVC) effects against residual disease. Among novel therapeutics for GVHD, oncolytic viruses such as myxoma virus (MYXV) are receiving increased attention due to their dual role in controlling GVHD while preserving or augmenting GVC. This review focuses on the molecular basis of GVHD, as well as state-of-the-art advances in developing novel therapies to prevent or control GVHD while minimizing impact on GVC. Recent literature regarding conventional and the emerging therapies are summarized, with special emphasis on virotherapy to prevent GVHD. Recent advances using preclinical models with oncolytic viruses such as MYXV to ameliorate the deleterious consequences of GVHD, while maintaining or improving the anti-cancer benefits of GVC will be reviewed.",
keywords = "Allo-HSCT, Allogeneic, Cancer, GVC, GVHD, Hematopoietic cell transplant, MYXV",
author = "Nancy Villa and Masmudur Rahman and Douglas McFadden and Cogle, {Christopher R.}",
year = "2016",
month = "3",
day = "1",
doi = "10.3390/V8030085",
language = "English (US)",
volume = "8",
journal = "Viruses",
issn = "1999-4915",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "3",

}

TY - JOUR

T1 - Therapeutics for graft-versus-host disease

T2 - From conventional therapies to novel virotherapeutic strategies

AU - Villa, Nancy

AU - Rahman, Masmudur

AU - McFadden, Douglas

AU - Cogle, Christopher R.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has a curative potential for many hematologic malignancies and blood diseases. However, the success of allo-HSCT is limited by graft-versus-host disease (GVHD), an immunological syndrome that involves inflammation and tissue damage mediated by donor lymphocytes. Despite immune suppression, GVHD is highly incident even after allo-HSCT using human leukocyte antigen (HLA)-matched donors. Therefore, alternative and more effective therapies are needed to prevent or control GVHD while preserving the beneficial graft-versus-cancer (GVC) effects against residual disease. Among novel therapeutics for GVHD, oncolytic viruses such as myxoma virus (MYXV) are receiving increased attention due to their dual role in controlling GVHD while preserving or augmenting GVC. This review focuses on the molecular basis of GVHD, as well as state-of-the-art advances in developing novel therapies to prevent or control GVHD while minimizing impact on GVC. Recent literature regarding conventional and the emerging therapies are summarized, with special emphasis on virotherapy to prevent GVHD. Recent advances using preclinical models with oncolytic viruses such as MYXV to ameliorate the deleterious consequences of GVHD, while maintaining or improving the anti-cancer benefits of GVC will be reviewed.

AB - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has a curative potential for many hematologic malignancies and blood diseases. However, the success of allo-HSCT is limited by graft-versus-host disease (GVHD), an immunological syndrome that involves inflammation and tissue damage mediated by donor lymphocytes. Despite immune suppression, GVHD is highly incident even after allo-HSCT using human leukocyte antigen (HLA)-matched donors. Therefore, alternative and more effective therapies are needed to prevent or control GVHD while preserving the beneficial graft-versus-cancer (GVC) effects against residual disease. Among novel therapeutics for GVHD, oncolytic viruses such as myxoma virus (MYXV) are receiving increased attention due to their dual role in controlling GVHD while preserving or augmenting GVC. This review focuses on the molecular basis of GVHD, as well as state-of-the-art advances in developing novel therapies to prevent or control GVHD while minimizing impact on GVC. Recent literature regarding conventional and the emerging therapies are summarized, with special emphasis on virotherapy to prevent GVHD. Recent advances using preclinical models with oncolytic viruses such as MYXV to ameliorate the deleterious consequences of GVHD, while maintaining or improving the anti-cancer benefits of GVC will be reviewed.

KW - Allo-HSCT

KW - Allogeneic

KW - Cancer

KW - GVC

KW - GVHD

KW - Hematopoietic cell transplant

KW - MYXV

UR - http://www.scopus.com/inward/record.url?scp=85007372767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007372767&partnerID=8YFLogxK

U2 - 10.3390/V8030085

DO - 10.3390/V8030085

M3 - Review article

C2 - 27011200

AN - SCOPUS:85007372767

VL - 8

JO - Viruses

JF - Viruses

SN - 1999-4915

IS - 3

M1 - 85

ER -